Abstract
Patients with cancer receiving chemotherapy often have chemotherapy-induced anemia (CIA) and reduced quality of life. Darbepoetin alfa can effectively treat CIA when administered at an extended dosing interval of once every 3 weeks (Q3W). Darbepoetin alfa administered Q3W may allow synchronization of darbepoetin alfa therapy with chemotherapy administered Q3W. This multicenter, open-label, 16-week study evaluated the effectiveness and safety of darbepoetin alfa administered as a fixed dose (300 μg) Q3W in patients with CIA. Eligible patients (≥18 years) were anemic (hemoglobin
| Original language | English |
|---|---|
| Pages (from-to) | 409-417 |
| Number of pages | 9 |
| Journal | Oncologist |
| Volume | 11 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2006 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Cancer Research
- Hematology
Cite this
Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. / Boccia, Ralph; Malik, Imtiaz A.; Raja, Vinay; Kahanic, Stephen; Liu, Randall; Lillie, Tom; Tomita, Dianne; Clowney, Billy; Silberstein, Peter T.
In: Oncologist, Vol. 11, No. 4, 04.2006, p. 409-417.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia
AU - Boccia, Ralph
AU - Malik, Imtiaz A.
AU - Raja, Vinay
AU - Kahanic, Stephen
AU - Liu, Randall
AU - Lillie, Tom
AU - Tomita, Dianne
AU - Clowney, Billy
AU - Silberstein, Peter T.
PY - 2006/4
Y1 - 2006/4
N2 - Patients with cancer receiving chemotherapy often have chemotherapy-induced anemia (CIA) and reduced quality of life. Darbepoetin alfa can effectively treat CIA when administered at an extended dosing interval of once every 3 weeks (Q3W). Darbepoetin alfa administered Q3W may allow synchronization of darbepoetin alfa therapy with chemotherapy administered Q3W. This multicenter, open-label, 16-week study evaluated the effectiveness and safety of darbepoetin alfa administered as a fixed dose (300 μg) Q3W in patients with CIA. Eligible patients (≥18 years) were anemic (hemoglobin
AB - Patients with cancer receiving chemotherapy often have chemotherapy-induced anemia (CIA) and reduced quality of life. Darbepoetin alfa can effectively treat CIA when administered at an extended dosing interval of once every 3 weeks (Q3W). Darbepoetin alfa administered Q3W may allow synchronization of darbepoetin alfa therapy with chemotherapy administered Q3W. This multicenter, open-label, 16-week study evaluated the effectiveness and safety of darbepoetin alfa administered as a fixed dose (300 μg) Q3W in patients with CIA. Eligible patients (≥18 years) were anemic (hemoglobin
UR - http://www.scopus.com/inward/record.url?scp=33645784831&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33645784831&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.11-4-409
DO - 10.1634/theoncologist.11-4-409
M3 - Article
C2 - 16614237
AN - SCOPUS:33645784831
VL - 11
SP - 409
EP - 417
JO - Oncologist
JF - Oncologist
SN - 1083-7159
IS - 4
ER -